Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
MDT's Cash-to-Debt is ranked lower than
75% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. MDT: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
MDT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.82 Max: No Debt
Current: 0.41
0.15
No Debt
Equity-to-Asset 0.56
MDT's Equity-to-Asset is ranked lower than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDT: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
MDT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.63 Max: 0.82
Current: 0.56
0.37
0.82
Debt-to-Equity 0.51
MDT's Debt-to-Equity is ranked lower than
71% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. MDT: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
MDT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.34 Max: 1.42
Current: 0.51
0.02
1.42
Debt-to-EBITDA 2.80
MDT's Debt-to-EBITDA is ranked lower than
64% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. MDT: 2.80 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MDT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.85  Med: 2.2 Max: 6.61
Current: 2.8
1.85
6.61
Interest Coverage 6.04
MDT's Interest Coverage is ranked lower than
82% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. MDT: 6.04 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 4.3  Med: 9.63 Max: 12.85
Current: 6.04
4.3
12.85
Piotroski F-Score: 8
Altman Z-Score: 3.16
Beneish M-Score: -2.64
WACC vs ROIC
4.53%
4.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 21.26
MDT's Operating Margin % is ranked higher than
88% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. MDT: 21.26 )
Ranked among companies with meaningful Operating Margin % only.
MDT' s Operating Margin % Range Over the Past 10 Years
Min: 20.67  Med: 25.72 Max: 29.47
Current: 21.26
20.67
29.47
Net Margin % 7.44
MDT's Net Margin % is ranked higher than
74% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MDT: 7.44 )
Ranked among companies with meaningful Net Margin % only.
MDT' s Net Margin % Range Over the Past 10 Years
Min: 7.44  Med: 16.1 Max: 22.35
Current: 7.44
7.44
22.35
ROE % 4.48
MDT's ROE % is ranked higher than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MDT: 4.48 )
Ranked among companies with meaningful ROE % only.
MDT' s ROE % Range Over the Past 10 Years
Min: 4.48  Med: 16.42 Max: 22.29
Current: 4.48
4.48
22.29
ROA % 2.46
MDT's ROA % is ranked higher than
61% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. MDT: 2.46 )
Ranked among companies with meaningful ROA % only.
MDT' s ROA % Range Over the Past 10 Years
Min: 2.46  Med: 8.73 Max: 11.99
Current: 2.46
2.46
11.99
ROC (Joel Greenblatt) % 73.27
MDT's ROC (Joel Greenblatt) % is ranked higher than
91% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. MDT: 73.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.55  Med: 70.37 Max: 79.72
Current: 73.27
51.55
79.72
3-Year Revenue Growth Rate 6.20
MDT's 3-Year Revenue Growth Rate is ranked higher than
63% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. MDT: 6.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.2  Med: 13.9 Max: 18.6
Current: 6.2
4.2
18.6
3-Year EBITDA Growth Rate 12.00
MDT's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. MDT: 12.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MDT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3.7  Med: 16.5 Max: 26.5
Current: 12
-3.7
26.5
3-Year EPS without NRI Growth Rate -2.00
MDT's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. MDT: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MDT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 15.6 Max: 27.1
Current: -2
-9.7
27.1
GuruFocus has detected 7 Warning Signs with Medtronic PLC MDT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDT's 30-Y Financials

Financials (Next Earnings Date: 2019-02-20)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

MDT Guru Trades in Q4 2017

Steven Cohen 1,589,025 sh (New)
First Pacific Advisors 5,250 sh (New)
Ray Dalio 25,152 sh (New)
Bill Nygren 3,190,000 sh (+30.74%)
Robert Olstein 117,000 sh (+5.41%)
T Rowe Price Equity Income Fund 3,200,000 sh (+3.23%)
Dodge & Cox 18,284,758 sh (+50.53%)
HOTCHKIS & WILEY 2,480,897 sh (+10.91%)
John Buckingham 25,150 sh (+19.06%)
Jeremy Grantham 4,081,011 sh (+0.14%)
Jeff Auxier 155,333 sh (+4.78%)
Mairs and Power 3,640,623 sh (+2.44%)
Caxton Associates 16,777 sh (+133.01%)
Diamond Hill Capital 4,066,070 sh (+18.14%)
Pioneer Investments 5,324,932 sh (+7.85%)
Mario Gabelli 29,314 sh (+23.06%)
First Eagle Investment 1,434 sh (unchged)
Steven Cohen 500,000 sh (unchged)
NWQ Managers Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Vanguard Health Care Fund 15,408,784 sh (-6.67%)
Ken Fisher 164,198 sh (-13.08%)
Joel Greenblatt 204,272 sh (-35.54%)
PRIMECAP Management 8,753,098 sh (-5.43%)
David Carlson 800,000 sh (-17.53%)
Paul Tudor Jones 43,331 sh (-26.36%)
Jim Simons 1,432,441 sh (-77.61%)
Barrow, Hanley, Mewhinney & Strauss 15,698,567 sh (-5.28%)
» More
Q1 2018

MDT Guru Trades in Q1 2018

Ken Fisher 216,956 sh (+32.13%)
T Rowe Price Equity Income Fund 3,320,000 sh (+3.75%)
Dodge & Cox 18,721,632 sh (+2.39%)
Joel Greenblatt 427,957 sh (+109.50%)
HOTCHKIS & WILEY 3,862,825 sh (+55.70%)
Jeremy Grantham 4,446,710 sh (+8.96%)
Jeff Auxier 161,248 sh (+3.81%)
Mairs and Power 3,668,495 sh (+0.77%)
First Pacific Advisors 16,400 sh (+212.38%)
Diamond Hill Capital 4,227,340 sh (+3.97%)
Vanguard Health Care Fund 15,408,784 sh (unchged)
Bill Nygren 3,190,000 sh (unchged)
First Eagle Investment Sold Out
Jim Simons Sold Out
Ray Dalio Sold Out
Signature Select Canadian Fund Sold Out
Robert Olstein 116,000 sh (-0.85%)
John Buckingham 25,086 sh (-0.25%)
PRIMECAP Management 8,179,292 sh (-6.56%)
David Carlson 560,000 sh (-30.00%)
Steven Cohen 741,199 sh (-53.36%)
Paul Tudor Jones 22,290 sh (-48.56%)
Caxton Associates 13,692 sh (-18.39%)
Barrow, Hanley, Mewhinney & Strauss 15,240,620 sh (-2.92%)
Pioneer Investments 4,086,932 sh (-23.25%)
Mario Gabelli 23,332 sh (-20.41%)
» More
Q2 2018

MDT Guru Trades in Q2 2018

Eaton Vance Worldwide Health Sciences Fund 117,565 sh (New)
Ken Fisher 226,743 sh (+4.51%)
T Rowe Price Equity Income Fund 3,460,000 sh (+4.22%)
Dodge & Cox 18,738,182 sh (+0.09%)
Joel Greenblatt 651,133 sh (+52.15%)
John Buckingham 25,106 sh (+0.08%)
Steven Cohen 823,622 sh (+11.12%)
Pioneer Investments 5,458,335 sh (+33.56%)
Mario Gabelli 23,744 sh (+1.77%)
David Carlson 560,000 sh (unchged)
Bill Nygren 3,190,000 sh (unchged)
Caxton Associates Sold Out
Vanguard Health Care Fund 14,533,984 sh (-5.68%)
Robert Olstein 86,000 sh (-25.86%)
HOTCHKIS & WILEY 3,627,625 sh (-6.09%)
PRIMECAP Management 8,162,952 sh (-0.20%)
Jeremy Grantham 3,568,527 sh (-19.75%)
Paul Tudor Jones 3,507 sh (-84.27%)
Mairs and Power 3,464,399 sh (-5.56%)
First Pacific Advisors 8,950 sh (-45.43%)
Diamond Hill Capital 4,018,635 sh (-4.94%)
Barrow, Hanley, Mewhinney & Strauss 14,589,501 sh (-4.27%)
Jeff Auxier 159,098 sh (-1.33%)
» More
Q3 2018

MDT Guru Trades in Q3 2018

Jim Simons 1,740,190 sh (New)
Stanley Druckenmiller 372,500 sh (New)
Ron Baron 2,722 sh (New)
Ken Fisher 233,816 sh (+3.12%)
Pioneer Investments 7,772,613 sh (+42.40%)
Joel Greenblatt 663,551 sh (+1.91%)
Paul Tudor Jones 11,351 sh (+223.67%)
John Buckingham 25,181 sh (+0.30%)
Eaton Vance Worldwide Health Sciences Fund 117,565 sh (unchged)
First Pacific Advisors 8,950 sh (unchged)
Bill Nygren 3,190,000 sh (unchged)
T Rowe Price Equity Income Fund 3,385,000 sh (-2.17%)
Vanguard Health Care Fund 13,104,084 sh (-9.84%)
David Carlson 460,000 sh (-17.86%)
Mario Gabelli 23,241 sh (-2.12%)
Robert Olstein 70,920 sh (-17.53%)
Barrow, Hanley, Mewhinney & Strauss 12,332,151 sh (-15.47%)
PRIMECAP Management 7,480,995 sh (-8.35%)
Diamond Hill Capital 3,886,612 sh (-3.29%)
Jeremy Grantham 3,480,300 sh (-2.47%)
Mairs and Power 3,237,193 sh (-6.56%)
HOTCHKIS & WILEY 3,183,899 sh (-12.23%)
Steven Cohen 46,400 sh (-94.37%)
Jeff Auxier 157,198 sh (-1.19%)
Dodge & Cox 17,662,282 sh (-5.74%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:ABT, NYSE:SYK, NAS:ISRG, NYSE:BSX, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDTN.Mexico, MDT.Switzerland, 0Y6X.UK,
Headquarter Location:Ireland
Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments.

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for about 45% of the company's total sales.

Guru Investment Theses on Medtronic PLC

Jeff Auxier Comments on Medtronic - Nov 08, 2018

Hoping to take advantage of the rapidly growing medical sector, Medtronic (NYSE:MDT) has focused on four high growth areas: Cardiac and Vascular, Restorative Therapies, Minimally Invasive Therapies, and Diabetes. The diabetes group has seen particularly strong growth from the MiniMed 670G featuring Smartguard, which is the world’s first hybrid closed loop insulin system. The Tax Cuts and Jobs Act freed up over 40% of their cash helping them towards their goal of returning 50% of free cash flow to shareholders.





From Jeff Auxier (Trades, Portfolio)'s third-quarter 2018 shareholder commentary.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Medtronic - Aug 03, 2017

Deeply oversold in 2016 political uncertainties, the world's largest standalone medical technology company rebounded sharply for the quarter. A leader in biomedical devices, they sold their medical supplies business for $6.1 billion and will pay down debt and repurchase shares.


From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Medtronic plc - May 09, 2017

Medtronic is a leader in implantable biomedical devices. Back in 2001 the stock traded at 37.5 times earnings and this past quarter traded down to 13 times earnings with a fortress balance sheet and a 7% free cash flow yield. They continue to be a leader in medical technology as their world’s smallest pacemaker, Micra, accelerates US sales driving pacemaker market growth. They generate over $5 billion in free cash flow annually.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Medtronic PLC

Jeff Auxier Comments on Medtronic Guru stock highlight
Hoping to take advantage of the rapidly growing medical sector, Medtronic (NYSE:MDT) has focused on four high growth areas: Cardiac and Vascular, Restorative Therapies, Minimally Invasive Therapies, and Diabetes. The diabetes group has seen particularly strong growth from the MiniMed 670G featuring Smartguard, which is the world’s first hybrid closed loop insulin system. The Tax Cuts and Jobs Act freed up over 40% of their cash helping them towards their goal of returning 50% of free cash flow to shareholders.
Read more...
Medtronic Co-Founder Earl Bakken Passes Away at Age 94
Late-Breaking Clinical Study Results Demonstrate Exceptional Safety and Efficacy Outcomes for Resolute Onyx(TM) DES
Medtronic Presents IN.PACT Global Study Three-Year Data and Total IN.PACT(TM) Imaging and Propensity Analyses
Medtronic to Acquire Mazor Robotics
Top Insider Buys Highlight for the Week of Aug. 24 Insiders buy Medtronic, Starbucks, Advance Auto, Andeavor
The largest Insider Buys this week were Medtronic PLC (NYSE:MDT), Starbucks Corp. (NASDAQ:SBUX), Advance Auto Parts Inc. (NYSE:AAP) and Andeavor Logistics LP (NYSE:ANDX). Read more...
What You Need to Know About Medtronic’s Earnings Company posts revenue, earnings beat
Medical device manufacturer Medtronic PLC (NYSE:MDT) reported first-quarter 2019 results on Tuesday morning, beating consensus estimates. Read more...
5 Companies Hit 52-Week Highs Medtronic, Waste Management, Williams Partners, Mosaic and Praxair achieve annual milestone
According to GuruFocus' list of 52-week highs, these stocks have reached their 52-week highs. Read more...
Market Trends Toward New Normal in Applied Optoelectronics, Integra LifeSciences, Medtronic, Workhorse Group, Platform Specialty Products, and Career Education — Emerging Consolidated Expectations, Analyst Ratings
Medtronic Launches the MiniMed(TM) 670G System Performance Guarantee for Payers and Employers

Ratios

vs
industry
vs
history
PE Ratio 57.86
MDT's PE Ratio is ranked lower than
66% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. MDT: 57.86 )
Ranked among companies with meaningful PE Ratio only.
MDT' s PE Ratio Range Over the Past 10 Years
Min: 10.17  Med: 21.55 Max: 59.11
Current: 57.86
10.17
59.11
Forward PE Ratio 18.66
MDT's Forward PE Ratio is ranked higher than
85% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. MDT: 18.66 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 57.86
MDT's PE Ratio without NRI is ranked lower than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. MDT: 57.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.17  Med: 21.55 Max: 59.11
Current: 57.86
10.17
59.11
Price-to-Owner-Earnings 30.55
MDT's Price-to-Owner-Earnings is ranked higher than
64% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. MDT: 30.55 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.24  Med: 18.96 Max: 37.87
Current: 30.55
9.24
37.87
PB Ratio 2.60
MDT's PB Ratio is ranked higher than
62% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. MDT: 2.60 )
Ranked among companies with meaningful PB Ratio only.
MDT' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 2.56 Max: 5.57
Current: 2.6
1.78
5.57
PS Ratio 4.28
MDT's PS Ratio is ranked lower than
55% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. MDT: 4.28 )
Ranked among companies with meaningful PS Ratio only.
MDT' s PS Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.53 Max: 4.55
Current: 4.28
1.92
4.55
Price-to-Free-Cash-Flow 26.71
MDT's Price-to-Free-Cash-Flow is ranked higher than
52% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. MDT: 26.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.18  Med: 14.75 Max: 33.07
Current: 26.71
9.18
33.07
Price-to-Operating-Cash-Flow 21.99
MDT's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. MDT: 21.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.13  Med: 12.8 Max: 25.54
Current: 21.99
8.13
25.54
EV-to-EBIT 22.71
MDT's EV-to-EBIT is ranked higher than
59% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. MDT: 22.71 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.6  Med: 16.15 Max: 31
Current: 22.71
8.6
31
EV-to-EBITDA 15.99
MDT's EV-to-EBITDA is ranked higher than
61% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. MDT: 15.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 13.45 Max: 23.6
Current: 15.99
7.3
23.6
EV-to-Revenue 4.72
MDT's EV-to-Revenue is ranked lower than
57% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. MDT: 4.72 )
Ranked among companies with meaningful EV-to-Revenue only.
MDT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 3.5 Max: 6.4
Current: 4.72
2.3
6.4
PEG Ratio 8.77
MDT's PEG Ratio is ranked lower than
84% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. MDT: 8.77 )
Ranked among companies with meaningful PEG Ratio only.
MDT' s PEG Ratio Range Over the Past 10 Years
Min: 1.09  Med: 4.08 Max: 43.2
Current: 8.77
1.09
43.2
Shiller PE Ratio 31.55
MDT's Shiller PE Ratio is ranked higher than
74% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. MDT: 31.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
MDT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.42  Med: 23.3 Max: 34.88
Current: 31.55
14.42
34.88
Current Ratio 2.56
MDT's Current Ratio is ranked lower than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. MDT: 2.56 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.4 Max: 6.8
Current: 2.56
0.88
6.8
Quick Ratio 2.11
MDT's Quick Ratio is ranked higher than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. MDT: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.9 Max: 6.46
Current: 2.11
0.66
6.46
Days Inventory 149.46
MDT's Days Inventory is ranked lower than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. MDT: 149.46 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 133.79  Med: 142.57 Max: 164.01
Current: 149.46
133.79
164.01
Days Sales Outstanding 69.00
MDT's Days Sales Outstanding is ranked lower than
53% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. MDT: 69.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.69  Med: 79.94 Max: 92.09
Current: 69
68.69
92.09
Days Payable 70.70
MDT's Days Payable is ranked higher than
59% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. MDT: 70.70 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 39.63  Med: 60.67 Max: 93.14
Current: 70.7
39.63
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.01
MDT's Dividend Yield % is ranked higher than
83% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. MDT: 2.01 )
Ranked among companies with meaningful Dividend Yield % only.
MDT' s Dividend Yield % Range Over the Past 10 Years
Min: 0.97  Med: 2.04 Max: 2.93
Current: 2.01
0.97
2.93
Dividend Payout Ratio 1.15
MDT's Dividend Payout Ratio is ranked higher than
71% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.32 vs. MDT: 1.15 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MDT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.29  Med: 0.39 Max: 1.15
Current: 1.15
0.29
1.15
3-Year Dividend Growth Rate 14.70
MDT's 3-Year Dividend Growth Rate is ranked higher than
64% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 9.70 vs. MDT: 14.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MDT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.6  Med: 16.4 Max: 30.2
Current: 14.7
7.6
30.2
Forward Dividend Yield % 2.09
MDT's Forward Dividend Yield % is ranked higher than
82% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. MDT: 2.09 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.75
MDT's 5-Year Yield-on-Cost % is ranked higher than
84% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. MDT: 3.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MDT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.81  Med: 3.81 Max: 5.47
Current: 3.75
1.81
5.47
3-Year Average Share Buyback Ratio 1.60
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. MDT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: 0 Max: 2.5
Current: 1.6
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.46
MDT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. MDT: 1.46 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.95 Max: 8.6
Current: 1.46
0.76
8.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.41
MDT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
85% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. MDT: 5.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MDT' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 1.51 Max: 5.09
Current: 5.41
0.54
5.09
Price-to-Median-PS-Value 1.21
MDT's Price-to-Median-PS-Value is ranked lower than
54% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. MDT: 1.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.16 Max: 3.58
Current: 1.21
0.42
3.58
Price-to-Peter-Lynch-Fair-Value 10.30
MDT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
94% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDT: 10.30 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MDT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.86  Med: 2.16 Max: 10.3
Current: 10.3
0.86
10.3
Earnings Yield (Greenblatt) % 4.40
MDT's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. MDT: 4.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.2  Med: 6.2 Max: 11.6
Current: 4.4
3.2
11.6
Forward Rate of Return (Yacktman) % 9.38
MDT's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. MDT: 9.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4  Med: 9.6 Max: 19.8
Current: 9.38
4
19.8

More Statistics

Revenue (TTM) (Mil) $30,378.00
EPS (TTM) $ 1.65
Beta0.66
Volatility19.61%
52-Week Range $76.41 - 100.15
Shares Outstanding (Mil)1,343.05

Analyst Estimate

Apr19 Apr20 Apr21
Revenue (Mil $) 30,609 31,959 33,600
EBIT (Mil $) 7,823 8,327 9,933
EBITDA (Mil $) 10,443 10,988 12,789
EPS ($) 4.09 4.50 4.43
EPS without NRI ($) 4.09 4.50 4.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.61%
Dividends per Share ($) 1.98 2.14 2.37

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}